Jim Cramer Says Revolution Medicines “Is a Speculative Situation”

Company Overview - Revolution Medicines, Inc. (NASDAQ:RVMD) is a clinical-stage oncology company focused on developing targeted therapies for RAS-driven cancers [2] - RAS refers to a family of genes that produce proteins that control cell growth and division [2] Recent Developments - On October 17, Raymond James increased its price target for RVMD from $72 to $76 and maintained a Strong Buy rating [2] - The firm's analysis highlighted that RVMD's daraxonrasib has been accepted into the FDA Commissioner's National Priority Review, which is expected to expedite its market entry for second-line RAS-mutant pancreatic cancer [2] Market Sentiment - Jim Cramer described RVMD as a speculative situation in the oncology sector, expressing a personal connection to the fight against cancer and a general support for speculative stocks aiming to cure cancer [1]